Our assay helps to identify cancer predisposition – Lynch Syndrome

MethylDetect’s assay targetting MLH1 gene is now a part of the NICE-mandated Lynch Syndrome pre-screen test. The results showing the performance of our MLH1 methylation testing assays, performed in collaboration with Sarah Cannon Molecular Diagnostics, https://sarahcannon-md.co.uk , were presented at the National Cancer Research Institute conference 2018. see: MLH1 Promoter Hypermethylation: Development and Preliminary Validation of a Methylation-Specific High…